Skip to Content


Treatment for Parkinson's Disease

Teva Receives Approvable Letter for Agilect (rasagiline)

JERUSALEM, July 5, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for once-daily Agilect (rasagiline mesylate) as a treatment for Parkinson's disease (PD) as initial monotherapy in early PD patients and as adjunct therapy to levodopa in moderate-to-advanced stages of the disease. Following the approvable letter, Teva will work together with the FDA to complete the process of receiving final approval as soon as possible.

Israel Makov, President and CEO of Teva commented: "We are very pleased to receive this approvable letter, which is a major regulatory milestone in the approval process of Agilect." Mr. Makov added, "Today represents another important step towards Teva being able to offer a new treatment option to the many patients who currently suffer from Parkinson's disease in the United States."

Teva Neuroscience, Inc. and Eisai Inc. will co-promote Agilect in the United States once approved by the FDA and Teva and H. Lundbeck A/S will co-promote the product in Europe, once approved there.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 25 pharmaceutical companies in the world. The company develops, manufactures, and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. Close to 90 percent of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.

Posted: July 2004

Related Articles

Azilect (rasagiline mesylate) FDA Approval History